START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

NCT05492682 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma (Skin)
Triple-Negative Breast Cancer
Non-Small Cell Lung Cancer
Synovial Sarcoma
Myxoid Liposarcoma
Colorectal Cancer
Osteosarcoma
Sarcoma

Interventions

DRUG: PeptiCRAd-1
DRUG: Cyclophosphamide
DRUG: Pembrolizumab

Sponsor

Valo Therapeutics Oy